Monday, March 03, 2025 | 09:09 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

USFDA issues Form 483 to Sun Pharma's Dadra plant over quality issues

As per media reports, the regulator is learnt to have found deficiencies relating to medicine quality, data collection, maintenance as well as quality control unit

pharmaceuticals
Premium

Vinay Umarji Ahmedabad
Raising concerns over data collection and quality control unit, the US Food and Drug Administration (USFDA) has reportedly issued a Form 483 to Sun Pharmaceutical Industries Ltd for its Dadra plant.

As per media reports, the regulator is learnt to have found deficiencies relating to medicine quality, data collection, maintenance as well as quality control unit. After an inspection of Sun Pharma's Dadra plant in March this year, USFDA has reportedly issued 11 observations on the site.

The observations include lack of written procedures for production and process controls designed to assure that drug products have identity, strength, quality, and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in